Trial Profile
A retrospective trial to assess certolizumab pegol in paediatric patients with polyarticular juvenile idiopathic arthritis that did not sufficiently respond to pre-treatment with etanercept + methotrexate or adalimumab + methotrexate
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Aug 2015
Price :
$35
*
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- 07 Aug 2015 New trial record
- 10 Jun 2015 Results presented at the 16th Annual Congress of the European League Against Rheumatism.